Visualization and quantitation of epidermal growth factor receptor homodimerization and activation with a proximity ligation assay.

about

Visualization and quantitation of epidermal growth factor receptor homodimerization and activation with a proximity ligation assay.

Item

http://www.wikidata.org/entity/Q42700828

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Visualization and quantitation ...... th a proximity ligation assay.

@en

Visualization and quantitation ...... th a proximity ligation assay.

@nl

type

Item

label

Visualization and quantitation ...... th a proximity ligation assay.

@en

Visualization and quantitation ...... th a proximity ligation assay.

@nl

prefLabel

Visualization and quantitation ...... th a proximity ligation assay.

@en

Visualization and quantitation ...... th a proximity ligation assay.

@nl

P1476

Visualization and quantitation ...... th a proximity ligation assay.

@en

P2093

Akiko Fujii

http://www.w3.org/2001/XMLSchema#string

Isamu Okamoto

http://www.w3.org/2001/XMLSchema#string

Keiichi Ota

http://www.w3.org/2001/XMLSchema#string

Kentaro Tanaka

http://www.w3.org/2001/XMLSchema#string

Kohei Otsubo

http://www.w3.org/2001/XMLSchema#string

Taishi Harada

http://www.w3.org/2001/XMLSchema#string

Yoichi Nakanishi

http://www.w3.org/2001/XMLSchema#string

Yuko Tsuchiya

http://www.w3.org/2001/XMLSchema#string

P2860

Protein phosphorylation profiling using an in situ proximity ligation assay: phosphorylation of AURKA-elicited EGFR-Thr654 and EGFR-Ser1046 in lung cancer cells

Cetuximab for the treatment of colorectal cancer.

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

Erlotinib in previously treated non-small-cell lung cancer

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Platinum-based chemotherapy plus cetuximab in head and neck cancer.

ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling.

Annotation of human cancers with EGFR signaling-associated protein complexes using proximity ligation assays

P304

72127-72132

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.19552

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-07-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29069773

http://www.w3.org/2001/XMLSchema#string

P932

5641116

http://www.w3.org/2001/XMLSchema#string